Inmune Bio Inc (INMB) financials
Inmune Bio revenue and earnings by year
Inmune Bio's revenue was $50,000 in the fiscal year to December 31, 2025, up 257.1% from the year before. Net income was -$45.9 million, -91866.0% of revenue. Since the fiscal year to December 31, 2020, revenue has grown 35.4% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 6 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue growth | 257.1% | -91.0% | -58.6% | 106.6% | 1545.5% | — |
| Operating income | -47 | -43 | -30 | -27 | -30 | -12 |
| Operating margin | -94766.0% | -304535.7% | -19187.7% | -7299.2% | -16762.4% | -111163.6% |
| Net income | -46 | -42 | -30 | -27 | -30 | -12 |
| Net margin | -91866.0% | -300585.7% | -19360.0% | -7299.2% | -16762.4% | -109990.9% |
| Diluted EPS | -$1.86 | -$2.11 | -$1.67 | -$1.52 | -$1.88 | -$0.99 |
| Free cash flow | -24 | -33 | -12 | -23 | -29 | -9 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open INMB in Markets.
See also: INMB returns
No forecast, no recommendation. This page describes Inmune Bio Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.